1. Home
  2. RGT vs OKYO Comparison

RGT vs OKYO Comparison

Compare RGT & OKYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royce Global Value Trust Inc.

RGT

Royce Global Value Trust Inc.

N/A

Current Price

$14.16

Market Cap

94.4M

Sector

Finance

ML Signal

N/A

Logo OKYO Pharma Limited

OKYO

OKYO Pharma Limited

SELL

Current Price

$1.07

Market Cap

78.2M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RGT
OKYO
Founded
1986
2007
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.4M
78.2M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
RGT
OKYO
Price
$14.16
$1.07
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $8.33
AVG Volume (30 Days)
15.3K
★ 282.3K
Earning Date
01-01-0001
07-20-2026
Dividend Yield
★ 1.43%
N/A
EPS Growth
N/A
N/A
EPS
★ 0.92
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$15.58
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.19
$1.00
52 Week High
$15.79
$3.20

Technical Indicators

Market Signals
Indicator
RGT
OKYO
Relative Strength Index (RSI) 39.44 33.79
Support Level $14.04 N/A
Resistance Level $14.80 $1.70
Average True Range (ATR) 0.30 0.13
MACD -0.08 -0.03
Stochastic Oscillator 0.00 20.23

Price Performance

Historical Comparison
RGT
OKYO

About RGT Royce Global Value Trust Inc.

Royce Global Value Trust Inc is a diversified closed-end investment company. The Fund spreads its investments across diversified sectors such as information technology, consumer discretionary, health care, materials, consumer staples and energy. Geographically, it has presence in the United Kingdom, Japan, the United States, Canada, France, Hong Kong and Germany.

About OKYO OKYO Pharma Limited

OKYO Pharma Ltd is a clinical-stage ophthalmology company focused on developing differentiated therapies for corneal and anterior segment diseases. It is advancing a pipeline designed to improve outcomes for patients suffering from debilitating ocular diseases that impact vision and ocular comfort. The company's main program, urcosimod, is being developed as a potential treatment for neuropathic corneal pain. Additionally, its development pipeline includes an exploratory candidate, OK-201, a non-opioid analgesic drug candidate, as a potential drug to treat acute and chronic ocular pain. The company has only one operating segment: the research and development of biotechnological and pharmaceutical products.

Share on Social Networks: